National bank 48 minutes ago by MT Newswires
01:33 PM EDT, 04/13/2023 (MT Newswires) -- Theratechnologies reported Q1/2023 financial results.
Key Takeaways:
Theratechnologies reported Q1/f23 results below estimates with revenues of US$19.9 million (vs. US$22.7 million NBF and US$21.5 million consensus), Adj. EBITDA of -$3.9 million (vs. -US$2.2 million NBF) and EPS of -US$0.11 (vs. -US$0.05 NBF and -US$0.05 consensus). The lower-than-expected results were due to inventory loading ahead of 2023 price increases. National Bank analyst Endri Leno is maintaining his forecasts unchanged (in line with guidance) given TH's fQ1 prescription growth -- the latter is expected to contribute to results in coming of quarters. "However, given the risk associated with the catch up to achieve guidance, we lower our target multiples for both EGRIFTA and Trogarzo."
Lowering target to C$2.25 (was C$3.25), maintain Sector Perform rating.
Price: 1.13, Change: +0.08, Percent Change: +7.62